GSK2256098 is a highly potent, ATP-competitive, and reversible FAK inhibitor [25], which is currently underway in clinical trials as a monotherapy or in combination with other drugs for patients with brain tumors or other cancers [26]. This evidence concerns the gene PTK2 and cancer.